Targeting Investigation and Treatment in Patients With Type 2 Myocardial Infarction

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 14, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions
Myocardial Infarction Type 2
Interventions
DIAGNOSTIC_TEST

Coronary computed tomography angiography

CT scan of the heart arteries

DIAGNOSTIC_TEST

Invasive coronary angiography

Invasive coronary angiography via the radial or femoral approach

DIAGNOSTIC_TEST

Transthoracic echocardiography

Ultrasound scan of the heart

DIAGNOSTIC_TEST

Cardiac MRI scan

An MRI scan to assess the heart structure and function

DRUG

Antiplatelet Drug (Aspirin or Statin)

Antiplatelet therapy for coronary artery disease

DRUG

Anticoagulants (Apixaban, Edoxaban, Rivaroxoban, Warfarin)

Anticoagulant therapy if atrial fibrillation identified (DOAC or Warfarin)

DRUG

Guideline directed heart failure therapy

Use of guideline approved heart failure treatments (ACE-inhibitor / angiotensin receptor blocker (ARB) / ARB and neprilysin inhibitor, mineralocorticoid receptor antagonist, beta blocker, SGLT-2 inhibitor, diuretic therapy)

DRUG

Statins (Cardiovascular Agents)

Statins will be recommended for patients with coronary plaque disease or hypercholesterolaemia

Trial Locations (2)

KY25AH

Victoria Hospital, Kirkcaldy

EH16 4SB

NHS Lothian, Edinburgh

All Listed Sponsors
collaborator

Chief Scientist Office of the Scottish Government

OTHER_GOV

lead

University of Edinburgh

OTHER